NRAS and melanoma: Furthermore, the melanoma cells from tumor-bearing mice treated with vemurafenib were more tolerant to BRAF inhibition than cells isolated from untreated tumors [30], and the protease inhibitor nelfinavir mesylate suppressed MITF expression and sensitizes BRAF and NRAS mutant melanoma to MAPK inhibitor treatment.